Author : • Sajjad H. Kadhim Al-Shuwailli, • Munib Ahmed Al-Zubaidi, • Dawood S. Abdoun,

Abstract : Background: The primary goal of central precocious puberty treatment is to preserve final adult height. Safe and effective treatment of central precocious puberty in the form of long-acting GnRH analogs has been available for many years. Aim of study: To study the clinical characters of patients with central precocious puberty and their response to GnRh agonist therapy. Patients and Method: A randomized clinical trial study that conducted at Pediatric Endocrinology Outpatient Clinic in Children Welfare Teaching Hospital / Medical City from 1st of November 2018 to 30th of October 2019. It included 83 patients presented to the hospital because of early pubertal development and diagnosed with central precocious puberty. Subcutaneous injections of GnRH agonist (goserelin acetate [Zoladex]) were administered to all patients. Patients were observed for weight, height and sex maturation rate in addition to laboratory data were taken after at least 12 months. Results: In this study, there were significant decrease in height, suppression of the significant increase in bone age, and a significant increase in BMI level after treatment compared to that before treatment. Basal LH, FSH estradiol & testosterone values after treatment decline to significant levels. Conclusion: GnRHa treatment for CPP is safe and can be curative by improving the predicted height and delaying the growth rate.

Volume and Issue
Full Article Download